Infant Bacterial Therapeutics AB (publ) announced at the Annual General Meeting held on May 4, 2022, Robert Molander resigned from the Board at his own request. At the same time, Robert is transferring to an operational role as Chief Commercial Officer within the management team for the company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
89.4 SEK | +1.82% | +2.52% | -0.67% |
1st Jan change | Capi. | |
---|---|---|
-0.67% | 108M | |
+4.06% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |
- Stock Market
- Equities
- IBT B Stock
- News Infant Bacterial Therapeutics AB
- Infant Bacterial Therapeutics AB Announces Management Changes